SLS - SELLAS Life Sciences to Host Corporate Update Call on March 26 2024 at 8:15 am ET | Benzinga
- Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) -
- Update on the Phase 2a Clinical Trial of SLS009 in relapsed/refractory AML, including topline data -
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update call on March 26, 2024, at 8:15 am ET.
Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS will provide an update on the Phase 3 REGAL study of galinpepimut-S (GPS) in AML, as well as the topline data for the 45mg cohort and preliminary data for the 60mg cohort from the Phase 2a study of SLS009 in relapsed/refractory AML.
| Corporate update call details are as follows: |
| Date: |
| Tuesday, March 26, 2024 |
| Time: |
| 8:15 a.m. Eastern Time |
| Dial-in (U.S.): |
| 1-877-423-9813 |
| International Dial-in: |
| 1-201-689-8573 |
| Webcast: |
| SELLAS Update Call |
About ...